Form 4: Harmony Biosciences Director Peter Anastasiou Granted Stock Options

Director Peter Anastasiou of Harmony Biosciences Holdings, Inc. received stock options on May 15, 2025.

Summary

• Peter Anastasiou, a director of Harmony Biosciences Holdings, Inc., was granted stock options on May 15, 2025.
• The stock options are for 14,522 shares of common stock at an exercise price of $34.23.
• The options vest fully on the earlier of May 15, 2026, or the date of the next annual meeting following the grant date, contingent upon continued service.
• Following the transaction, Anastasiou directly owns 14,522 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating a positive alignment of interests between management and shareholders. It's a routine event, hence a moderately positive sentiment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing performance and value creation.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with the company's long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biopharmaceutical industry.
• Companies like Jazz Pharmaceuticals and Biohaven also utilize stock options to incentivize their leadership teams.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, director, Harmony Biosciences, HRMY, beneficial ownership, Form 4, Anastasiou, equity securities